![]() |
|
|
Vol. 29, Issue 8, 1156-1161, August 2001
Neuropsychiatry Research Unit, Department of Psychiatry, University
of Saskatchewan, Saskatoon, Saskatchewan, Canada
(R)-N-(2-Heptyl)-N-methyl-propargylamine
(R-2HMP) and
(R)-N-(2-heptyl)-propargylamine
(R-2HPA) are analogs of R-deprenyl. R-Deprenyl, a selective monoamine oxidase B
inhibitor, is a mechanism-based inactivator of purified CYP2B1. The aim
of the present study was to determine whether R-2HMP and
R-2HPA behaved like deprenyl with respect to inhibiting
cytochrome P450 (CYP450) enzyme activity. The activities of CYP1A2 and
CYP1A1 were assessed by measuring the deethylation of 7-ethoxyresorufin
by liver microsomes obtained from control and
-naphthoflavone-treated female Wistar rats, respectively. CYP2B1
activity was assessed by measuring depentylation of 7-pentoxyresorufin
by liver microsomes obtained from phenobarbital-treated rats. The
activity of CYP1A1 was unaffected by 100 µM concentrations of
R-deprenyl, R-2HMP, or
R-2HPA. In contrast, the activities of CYP1A2 and CYP2B1
were significantly decreased. In general, the percentage of CYP1A2
activity remaining in the presence of 100 µM of one of these
propargylamines ranged from 45 to 56%, whereas 10% or less of CYP2B1
activity remained. No marked differences between the various
propargylamines were observed. The IC50 values for the
inhibition of CYP2B1 activity by R-deprenyl,
R-2HMP, and R-2HPA were found to be 2.6, 8.5, and 3.6 µM, respectively. The S-enantiomers of
deprenyl, 2HMP, and 2HPA also inhibited the activity of microsomal
CYP2B1. R-2HMP, R-2HPA, and
S-2HPA were found to be mechanism-based inactivators of
CYP2B1 activity. The inactivation constants
kinact and KI
were found to be as follows: R-deprenyl, 1.3 µM and
0.32 min
1; R-2HMP, 0.8 µM and 0.08 min
1; R-2HPA, 0.5 µM and 0.36 min
1; and S-2HPA, 0.24 µM and 0.18 min
1.
This article has been cited by other articles:
![]() |
E. C.K. Siu and R. F. Tyndale Selegiline Is a Mechanism-Based Inactivator of CYP2A6 Inhibiting Nicotine Metabolism in Humans and Mice J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 992 - 999. [Abstract] [Full Text] [PDF] |
||||